Aprea Therapeutics (NASDAQ:APRE) Price Target Lowered to $7.00 at Wedbush

Aprea Therapeutics (NASDAQ:APRE) had its price objective cut by Wedbush from $11.00 to $7.00 in a report released on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities research analysts have also weighed in on APRE. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective (down previously from $5.00) on shares of Aprea Therapeutics in a report on Thursday, January 29th. Zacks Research downgraded Aprea Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $5.50.

Aprea Therapeutics Stock Performance

Shares of APRE stock opened at $0.64 on Tuesday. The stock’s 50-day moving average is $0.87 and its two-hundred day moving average is $1.26. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $3.72. The firm has a market cap of $4.47 million, a price-to-earnings ratio of -0.30 and a beta of 1.48.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Wednesday, November 12th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.36). The business had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. As a group, research analysts predict that Aprea Therapeutics will post -2.55 EPS for the current year.

Insider Buying and Selling at Aprea Therapeutics

In other Aprea Therapeutics news, Director Marc Duey purchased 21,459 shares of the business’s stock in a transaction on Wednesday, December 10th. The stock was bought at an average cost of $1.17 per share, for a total transaction of $25,107.03. Following the acquisition, the director owned 256,155 shares of the company’s stock, valued at approximately $299,701.35. The trade was a 9.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 13.63% of the stock is currently owned by corporate insiders.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.